anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a proposal to conduct a pilot study to assess the feasibility of recruitment of Veteran smoker and support person (SP) dyads and study procedures in preparation for a large randomized pragmatic trial. Enhancing access and use of evidence-based tobacco cessation treatments and eliminating tobacco-related health disparities are top national and VA health services priorities. The prevalence of tobacco use is greater among Veterans compared to non-Veterans. From 2010-2015, 28.9% of women and 21.1% of male Veterans reported current cigarette smoking. Because our prior VHA trials enrolled about 94% men and the higher smoking rates among women, we will examine the feasibility of recruitment of an equal number of men and women Veteran smokers in this pilot study. Evidence-based cessation treatments (EBCTs) such as, tobacco quitlines, behavioral counseling, and pharmacotherapy, are greatly underutilized by Veteran smokers. This pilot project is innovative for evaluating social support networks as a proactive outreach approach to enhance cessation treatment utilization among Veteran smokers. The role of social network influences and social support on successful smoking cessation is established. Based on Cohen's theory of social support, our team developed a social support intervention for diverse family members, friends, and other adults who wanted to help a smoker quit. The intervention consists of written materials and a 1-call, 15-25 minute coaching session. The intervention goal is for support persons (SPs) to encourage their smoker to use EBCT.

We will conduct a randomized pilot trial within the national VHA health system to evaluate the feasibility of recruitment of smoker-SP dyads and other study procedures. Veteran smokers, regardless of level of readiness to quit, will be identified nationally using the VHA electronic health record (EHR) data base and proactively recruited. Interested smokers will be asked to identify a SP who will enroll. Participants will be randomized as smoker-SP dyads to the intervention (n= 15 dyads) or control condition (n= 15 dyads). All smoker participants will receive written resources and information on evidence-based cessation treatments. All SP participants will receive written materials. SP participants assigned to the intervention group will additionally receive a 1-call coaching session. Assessments for dyads in both study groups will be conducted at baseline and at 3-months post-randomization.

Our specific aims are to: (Aim 1) To assess the feasibility of recruitment of 30 Veteran smoker-SP dyads including enrollment of an equal number of men and women Veterans; and (Aim 2) To evaluate the feasibility of biochemical verification of the smoker's abstinence at 1-month follow-up using a remote collection method.

If the project is successful, we will have a blueprint for conducting a large randomized pragmatic trial. Preliminary data will be incorporated in a grant resubmission to the VA HSR\& D to support the feasibility of recruitment and other study procedures.
The control group will receive usual care including the medical care offered by the specialist out-patient clinic during 1-26 week. There are 2 post-test evaluations at 14th week and 26th week. From week 27 to week 40, this wait-list control group will receive the same EB-PRT as the intervention group.
STUDY OBJECTIVE: Few data are available on the association between the use of oxycodone in patients with chronic kidney disease (CKD) and acute respiratory conditions. The aim of this study was to investigate whether oxycodone is associated with an increased risk of acute respiratory conditions in patients with cancer and CKD compared with other opioids.
DESIGN AND SETTING: The data were obtained from a claims database in Japan. Patients with cancer and CKD who had received sustained-release opioids, including oral oxycodone, oral morphine, or transdermal fentanyl, between April 2014 and May 2021 were selected. The primary outcome was defined as an acute respiratory condition. Data for age and sex, morphine equivalent daily dose, concomitant use of specified medications, comorbidities defined based on the modified Charlson comorbidity index, substance use disorder, and lung cancer or metastatic lung cancer were investigated as covariates. Distribution of acute respiratory conditions was compared among the three sustained-release opioid groups using the log-rank test. Estimates of the incidence of acute respiratory conditions were compared among the groups using a Cox proportional hazards model with time-varying variables.
MAIN RESULTS: A significant difference in the distribution of acute respiratory conditions was found among the three groups (p < 0.01). Cox regression analysis showed a significantly higher risk of acute respiratory conditions with morphine (hazard ratio [HR]: 3.04, 95% confidence interval [CI]: 1.07-8.65, p = 0.04) compared with oxycodone but no significant difference in risk with oxycodone (HR 0.67, 95% CI: 0.32-1.38, p = 0.27) compared with fentanyl.
CONCLUSIONS: The findings suggest that the risk of acute respiratory conditions may be lower in patients with CKD who use oxycodone for cancer pain than in those who use morphine. Additionally, no difference in the risk of acute respiratory conditions was found between oxycodone and fentanyl use.
The application describes methods for producing artificial skeletal muscle tissue from pluripotent stem cells. A method for producing skeletal myoblasts, skeletal myotubes and satellite cells from pluripotent stem cells is also disclosed. During the described methods, there is directed differentiation and maturation of the pluripotent stem cells into skeletal myotubes and satellite cells. The application also describes artificial skeletal muscle tissue which has multinuclear skeletal muscle fibres with satellite cells. Furthermore, the invention relates to mesodermally differentiated skeletal myoblast precursor cells, myogenically specified skeletal myoblast precursor cells, skeletal myoblast cells, satellite cells and skeletal myotubes, which can be produced by means of the disclosed methods. The application also describes the use of skeletal muscle tissue or the disclosed cells in drug testing or in medicine. Lastly, the application relates to  in vitro  methods in which the skeletal muscle tissue or the disclosed cells are used.
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure 2,3 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 15 mcg azithromycin to test the susceptibility of microorganisms to azithromycin. The disk diffusion interpretive criteria are provided in Table 3. 

Table 3. Susceptibility Interpretive Criteria for Azithromycin Susceptibility Test Result Interpretive Criteria

  


aThe current absence of data on resistant strains precludes defining any category other than “susceptible”. If strains yield MIC results other than susceptible, they should be submitted to a reference laboratory for further testing. 

bSusceptibility of streptococci including, S. pneumoniae to azithromycin and other macrolides can be predicted by testing erythromycin. 

No interpretive criteria have been established for testing Neisseria gonorrhoeae. This species is not usually tested. 

A report of �susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable. A report of “intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable; other therapy should be selected.
Children are followed for 6 months, not receiving any treatment. After this follow-up period, children also receive incontinence treatment for 6 months.
The invention discloses an application of bacillus subtilis plasmin in medicines for treating silicosis. The bacillus subtilis plasmin is prepared by fermenting bacillus subtilis. The bacillus subtilis plasmin as an active component is used in medicines for treating silicosis, alone or in combination with other medicines. The bacillus subtilis plasmin can be matched with pharmaceutically acceptable auxiliary materials to prepare liquid medicament, capsule or tablet. The bacillus subtilis plasmin can lighten SiO  2  The induced silicosis inflammatory reaction controls lesions in early macrophage and lymphocyte stages, preventing proliferation of fibroblasts and progression of fibrosis. The bacillus subtilis plasmin has a certain blocking effect on the silicosis fibrosis process and can be used for preventing and treating silicosis fibrosis and assisting treatment.
The present invention relates to a cosmetic composition comprising a conjugated polymer and a manufacturing method thereof. According to the present invention, the cosmetic composition comprises conjugated polymer particles to effectively block a light of an infrared region and does not require an additional infrared blocking material. Specifically, the cosmetic composition has a transmittance of 20% or lower for a light of a wavelength range of 780-1,440 nm, a transmittance of 5% or lower for a light of a wavelength range of 1,500-2,500 nm, and a transmittance of 40% or lower for a light of a wavelength range of 290-400 nm to have excellent light blocking effects in ultraviolet and infrared regions. Specifically, infrared rays of 780-1,440 nm regions, which are main infrared wavelengths of skin heat aging, are blocked to effectively prevent skin aging by heat. Also, the cosmetic composition has excellent dispersion stability of particles to facilitate long-term use, and forms conjugated polymer particles in micro sizes to prevent absorption into human skin. Also, the present invention can provide an infrared-blocking cosmetic composition capable of blocking infrared rays when using only a small quantity of the product produced by a simple manufacturing process and an organic manufacturing method of particles dispersed in water.
If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age \>75years, weight \<60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
ECPs can give women a "second chance" to prevent an unintended pregnancy that might arise because of lack or improper/defective use of contraceptives. By using ECP, a woman can reduce her risk of pregnancy by at least 75%; however, there is little information on what distribution patterns and other factors are most likely to encourage ECP use. This study will compare the use and cost of two ECP distribution patterns: advance provision and emergency provision. It will also identify environmental, situational, and behavioral factors associated with ECP acceptance and use.

Participants in this study will be recruited from four family planning clinics in the Philadelphia area and five family planning clinics in the Pittsburgh area. Participants from the Philadelphia clinics will be given ECPs as part of a regular clinic visit (advance provision); participants from the Pittsburgh clinics will be given ECPs on an emergency basis (emergent provision). Each participant will complete a short intake form and will be issued a pager. Participants will be paged every month over an 18-month period as a reminder to respond to a short automated telephone survey on ECP, contraceptives, and pregnancy status. Approximately half of the participants will be randomly selected to participate in in-depth interviews at study entry and Months 9 and 18. Clinic visit data will augment the surveys to verify use of the clinic and contraceptive method and to develop cost data.
Program will meet twice a week for a 10-week period. Participants will be a part of gentle yoga sessions led by instructors specializing in the area.
PURPOSE: To provide a pharmacological compsn. which consists of an inhibitor of HIV aspartate protease as an effective component and is used for the procedure of the tumors of warmblooded animals. CONSTITUTION: This pharmacological compsn. contains the inhibitor of the HIV aspartate protease or its salts or its derivatives or its salts esterified in OH groups and at least one kind of pharmacologically permitted carriers. The effective component compd. is preferably the compd. of the formula (R1 is H, alkoxycarbonyl, heterocyclic carbonyl, benzylcarbonyl, heterocyclic sulfonyl; R1 is a bond, the bivalent residue of α-amino acid bonded like an N terminal to R1 ; R2 , R3 are phenyl, cyclohexyl; A1 is a bond, the bivalent residue of α-amino acid bonded like an N terminal to CO; A2 is the bivalent residue of α-amino acid bonded like an N terminal to A1 , or A1 and A2 are the bivalent residues of dipeptide; R4 , R5 form thiomorpholino, morpholino together with N to which they bond).
The invention provides a preparation method of a rhomotoxine hydrolysis product. The method comprises the following steps of: performing ester hydrolysis, amide hydrolysis and acidification on rhomotoxine serving as a reaction substrate; and performing resin desalination and a subsequent process to obtain the rhomotoxine hydrolysis product. The preparation method has the advantage that: the obtained rhomotoxine hydrolysis product is water-soluble and is easy for a human body to absorb. On the other hand, the rhomotoxine hydrolysis product can be adsorbed on resin, so that the hydrolysis product can be purified by using resin; and the resin can be recycled without being regenerated, so that the production process is simplified, the production cost is lowered, and the realization of continuous production is facilitated. The method has the advantages of simple reaction process, high efficiency, easiness for controlling, simple process, low energy consumption and high product purity. The rhomotoxine hydrolysis product prepared with the method has characteristic absorption at the position of 224 nanometers, high water solubility and low toxicity, and can well keep the drug action.
The present invention concerns novel pantothenone compounds having pantetheinase inhibitory activity as well as antiplasmodial activity. These compounds can suitably be used in therapeutic and or prophylactic treatment of malaria. Furthermore, the present invention provides combinations of pantothenone compounds and pantothenamides. Combining a pantothenone with a pantothenamide increases the antimalarial potency by an order of magnitude. It is hypothesized that inhibition of pantetheinase activity could protect pantothenamides against degradation by serum-derived pantetheinases, thereby revealing the hitherto unknown antimalaria activity of pantothenamides. The present invention thus, for the first time, makes available compounds and combinations of compounds for use in therapeutic and or prophylactic treatment of malaria infection in a human or animal subject in need thereof, relying on interference with host or pathogen-derived pantetheinase dependent pathways.
In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen atoms. The ring additionally includes four carbon atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon triple bond. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.  Invention compounds may also act as insecticides, and as fungicides.  Pharmaceutical compositions containing invention compounds also have wide utility.
Patients with unruptured intracranial aneurysms received dual antiplatelet agents (100mg of aspirin and 75mg of clopidogrel) for at least five days before coil embolization. One day prior to coiling, aspirin reaction units (ARU) and P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with proper aspirin and clopidogrel reaction units (ARU \< 550 and PRU 85 \~219) will be enrolled in this study. After stent-assisted coiling, dual antiplatelet treatment continued for 12 months; after that time, this therapy will be exchanged for daily oral 100mg of aspirin for 18 months after coiling.
PURPOSE:To manufacture quantitatively the titled apatite of high grade with high reproducibility at a low cost by reacting phosphoric acid or Ca phosphate with CaCO3 in a reaction medium contg. an org. solvent. CONSTITUTION:Phosphoric acid and/or Ca phosphate and CaCO3 are charged into a reaction vessel in a desired ratio of Ca/P, and a proper amount of water is added to prepare a slurry. An org. solvent is then added to the slurry, and reflux is carried out under heating. Deposited hydroxyapatite contg. carbonate is separated.
Belimumab was approved for active lupus nephritis (LN) in adults in the European Union and patients ≥ 5 years of age in the USA based on a Phase 3, double-blind, placebo-controlled, 104-week study. The study evaluated the efficacy of belimumab plus background standard therapy in adults with active LN using an intravenous (IV) dose of 10 mg/kg. A longitudinal analysis of Primary Efficacy Renal Response (PERR) and Complete Renal Response (CRR) was performed to assess whether patients with high proteinuria at the start of belimumab treatment would benefit from a higher dose. Responder probability was modeled as a logistic regression with probability a function of time and treatment (belimumab or placebo). Dropout risk at each visit was incorporated into a joint model of efficacy response; only efficacy data prior to dropout events (belimumab discontinuation, treatment failure, or withdrawal) were included. Average belimumab concentration over the first 4 and 12 weeks and baseline proteinuria were considered as continuous covariates. In general, renal response (PERR and CRR) over time was higher in patients receiving belimumab than in those receiving placebo. Baseline proteinuria was considered the most relevant predictor of renal response, with reduced efficacy in patients with increased proteinuria for both belimumab or placebo treatment. For belimumab-treated patients, belimumab exposure was not found to be an important predictor of renal response. In conclusion, the 10 mg/kg IV dose was considered appropriate in all patients and there was no evidence to suggest a higher response would be achieved by increasing the dose.
AIM OF THE STUDY: Cholestasis induces severe liver injury and subsequent liver fibrosis. However, a comprehensive understanding of the relationships between liver fibrosis and cholestasis-induced changes in metabolites in the gut and fibrotic liver tissue and in the gut microbiota is insufficient.
METHODS: Common bile duct ligation (BDL) was employed to establish a cholestatic liver fibrosis model in mice for 26 days. Fibrotic liver tissue and the gut contents were collected. Untargeted metabolomics was conducted for the determination of metabolites in the gut contents and liver tissues. Metagenomics was adopted to explore the gut microbiota.
RESULTS: The metabolites in the gut contents and liver tissues between normal and cholestatic liver fibrosis mice were highly distinct. Beta-alanine metabolism and glutathione metabolism were downregulated in the gut of the BDL group. Galactose metabolism, biosynthesis of unsaturated fatty acids, and ABC transporters were upregulated in the gut and downregulated in the liver of the BDL group. Arginine biosynthesis, taurine and hypotaurine metabolism, arginine and proline metabolism, and primary bile acid biosynthesis were downregulated in the gut and upregulated in the liver of the BDL group. Metagenomic analysis revealed that the alpha diversity of the microbiota in the BDL group decreased. The altered structure of the gut microbiota in the BDL group led to the hypofunction of important metabolic pathways (such as folate biosynthesis, histidine metabolism, thiamine metabolism, biotin metabolism, and phenylalanine, tyrosine and tryptophan biosynthesis) and enzymes (such as NADH, DNA helicase, and DNA-directed DNA polymerase). Correlation analyses indicated that certain gut microbes were associated with gut and liver metabolites.
CONCLUSIONS: Untargeted metabolomics and metagenomics provided comprehensive information on gut and liver metabolism and gut microbiota in mice with cholestatic liver fibrosis. Therefore, significantly altered bacteria and metabolites may help provide some targets against cholestatic liver fibrosis in the future.
Aerobic physical exercise protocol of moderate intensity, for 12 weeks, 3 sessions per week, about 12 minutes. Physical activity chosen will be pedaling on a static bike.
A decision support engine provides a table of actual and predicted financial results particular to a selected medical equipment. A database stores parameter data of various medical equipment belonging to the organization. The stored parameters may include purchase date and price. An appraisal module uses the parameter data to generate an appraised value of each of the medical equipment. Upon selection by a user of a specific equipment, the decision support module provides past period financial results attributable to the selected equipment, and predicted financial results that may be achieved upon upgrade or replacement of the equipment by newly purchased or leased equipment. The entire system may reside in the cloud.
PURPOSE:To provide an external agent for skin for preventing the aging of skin such as generation of wrinkle by effectively eliminating hydroxy radical and/or singlet oxygen formed in the skin by the metabolism in vivo, exposure to solar ultraviolet rays, etc. CONSTITUTION:Extracted liquid and/or extracted component of one or more kinds of plants selected from Hamamelis (Hamamelis japonica Sieb. et Zucc., Hamamelis obtusata Makino and Hamamelis virginiana L.), Japanese oak (Quercus serata Thunb.), OHNARA (Quercus crispula Blume), chestnut tree (Aesculus hippocastanum L.) and burnet (Sanguisorba officinalis L.) are compounded as an agent for eliminating hydroxy radical and/or singlet oxygen. The above active oxygen species generated in the skin by the metabolism in vivo, exposure to solar ultraviolet rays, etc., can be eliminated with a small amount of the agent to exhibit excellent effect for preventing the aging of skin. It has excellent stability and safety.